Morgan Stanley Maintains Bristol-Myers Squibb Company - Preferred Security (BMYMP) Underweight Recommendation

Morgan Stanley maintained an Underweight on Bristol-Myers Squibb’s preferred security (OTCPK:BMYMP) on Dec. 12, 2025, even as the average one‑year analyst price target stood at $907.12 as of Dec. 6 (range $565.01–$1,206.72), implying 22.58% upside from the $740 close. Data shows projected annual revenue of 49,029MM (up 2.07%) and projected non‑GAAP EPS of 8.29; institutional ownership is modest and stable with 14 funds holding ~1.38M shares (one new holder last quarter) and average portfolio weight rising to 0.15%. The juxtaposition of an MS Underweight and a material consensus upside underscores analyst divergence on valuation and suggests monitoring catalysts that could resolve the gap.

Analysis

Morgan Stanley maintained an Underweight on Bristol‑Myers Squibb preferred security (OTCPK:BMYMP) on December 12, 2025, while the average one‑year analyst price target as of December 6 stood at $907.12 (range $565.01–$1,206.72), implying 22.58% upside from the $740 close. The juxtaposition of an institutional sell/underweight view with a materially positive consensus target highlights clear analyst divergence on valuation and risk.

Company projections in the report show annual revenue of $49,029MM (up 2.07%) and projected non‑GAAP EPS of 8.29, while institutional positioning is modest and broadly stable: 14 funds hold ~1.38M shares (one new owner last quarter) and average portfolio weight rose to 0.15% (+16.99%). Largest reported holders include ARBFX (858K) and GAAVX (195K), with no quarter‑over‑quarter share changes for those funds.

The wide price target dispersion ($565–$1,206) and mixed sentiment score indicate valuation uncertainty rather than a clear catalyst for re‑rating; the market‑impact score is low (0.18), suggesting limited near‑term trading momentum from institutional flows. Investors should watch earnings/revision activity and any shifts in institutional ownership or analyst positioning to resolve the divergence before materially changing exposure.

Key Decisions for Investors

• Maintain conservative position sizing or hedge existing BMYMP exposure given Morgan Stanley's Underweight versus a consensus target implying 22.58% upside
• Monitor incoming revenue and non‑GAAP EPS revisions relative to the current projections (revenue $49,029MM, +2.07%; EPS 8.29) and any changes in the 14 institutional holders as confirmation of the consensus view
• Consider opportunistic accumulation only if price moves toward the low analyst target ($565.01) or following confirmed catalyst‑driven upgrades that narrow the wide target range
• If holding material positions, evaluate protective hedges or a tactical reduction in weight given modest institutional ownership (1.38M shares, average weight 0.15%) and the current mixed sentiment